Brandes, Florian http://orcid.org/0000-0003-3741-287X
Borrmann, Melanie http://orcid.org/0000-0002-0741-616X
Buschmann, Dominik http://orcid.org/0000-0003-0460-6459
Meidert, Agnes S. http://orcid.org/0000-0002-5212-9071
Reithmair, Marlene http://orcid.org/0000-0002-9113-9643
Langkamp, Markus
Pridzun, Lutz
Kirchner, Benedikt http://orcid.org/0000-0003-3878-0148
Billaud, Jean-Noël
Amin, Nirav M.
Pearson, Joseph C.
Klein, Matthias http://orcid.org/0000-0001-9064-6865
Hauer, Daniela
Gevargez Zoubalan, Clarissa
Lindemann, Anja
Choukér, Alexander http://orcid.org/0000-0002-0133-4104
Felbinger, Thomas W.
Steinlein, Ortrud K. http://orcid.org/0000-0003-4311-6276
Pfaffl, Michael W. http://orcid.org/0000-0002-3192-1019
Kaufmann, Ines http://orcid.org/0000-0003-3556-0713
Schelling, Gustav http://orcid.org/0000-0002-6538-0652
Clinical trials referenced in this document:
Documents that mention this clinical trial
Progranulin signaling in sepsis, community-acquired bacterial pneumonia and COVID-19: a comparative, observational study
https://doi.org/10.1186/s40635-021-00406-7
Funding for this research was provided by:
Bundesministerium für Wirtschaft und Energie (KF2664503CS1)
Universitätsklinik München
Article History
Received: 21 April 2021
Accepted: 22 July 2021
First Online: 3 September 2021
Declarations
:
: FB, MB, DB, GS, MR, BK, MK, DH, CGZ, ASM, AL, AC, OS, GS, MP, TF have no conflict of interest; LP and ML are employees of MEDIAGNOST, Reutlingen, Germany which developed and markets the progranulin assay used in the study, and hold a patent on progranulin together with IK. JNB, NMA, JCP are employees of Qiagen Digital Insights, which markets the <i>Ingenuity Pathway Analysis</i> software package used for data analysis in the study.
: For studying the exploratory cohort, written approval was obtained from the Ethics Committee of the Friedrich-Schiller-University of Jena, Germany (Protocol# 2242-03/08, EudoraCT# 2006-006984-21, trial registration number NCT00832039) in cooperation with the local Ethics Committee of the Ludwig-Maximilians-University of Munich, Germany (amendment 13.01.2010). The confirmatory study was approved by the Ethics Committee of the Medical Faculty of the University of Munich under a separate protocol (protocol #551-14, trial registration number NCT03280576). All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Written informed consent for publication of blinded personal data was obtained from each participant or the patient’s legal representative.
: All study participants gave informed consent for publishing blinded personal data and the use of materials obtained during the study for laboratory analysis.